Informace o publikaci

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Autoři

HALÁMKOVÁ Jana KISS Igor PAVLOVSKÝ Zdeněk JARKOVSKÝ Jiří TOMÁŠEK Jiří TUČEK Štěpán HANAKOVA Lada MOULIS Mojmír ČECH Zbyněk ZAVŘELOVÁ Jiřina PENKA Miroslav

Rok publikování 2011
Druh Článek v odborném periodiku
Časopis / Zdroj Hepatogastroenterology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.5754/hge10232
Obor Ostatní lékařské obory
Klíčová slova Colorectal cancer; Plasminogen activator system; PAI 1; PAI 2; uPA; uPAR
Popis Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. Conclusions: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info